Your browser is no longer supported. Please, upgrade your browser.
Galecto, Inc.
Index- P/E- EPS (ttm)-1.70 Insider Own0.20% Shs Outstand25.26M Perf Week-0.23%
Market Cap112.65M Forward P/E- EPS next Y-2.12 Insider Trans21.27% Shs Float22.38M Perf Month-12.20%
Income-42.50M PEG- EPS next Q-0.54 Inst Own60.40% Short Float1.12% Perf Quarter-21.89%
Sales- P/S- EPS this Y19.40% Inst Trans0.32% Short Ratio0.21 Perf Half Y-64.85%
Book/sh6.04 P/B0.73 EPS next Y8.20% ROA- Target Price- Perf Year-
Cash/sh4.30 P/C1.02 EPS next 5Y47.60% ROE- 52W Range4.03 - 17.99 Perf YTD-64.91%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.10% Beta-
Dividend %- Quick Ratio21.10 Sales past 5Y- Gross Margin- 52W Low6.70% ATR0.29
Employees28 Current Ratio21.10 Sales Q/Q- Oper. Margin- RSI (14)43.11 Volatility4.91% 6.38%
OptionableYes Debt/Eq0.00 EPS Q/Q-128.90% Profit Margin- Rel Volume0.04 Prev Close4.39
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.19M Price4.30
Recom1.20 SMA20-2.44% SMA50-11.96% SMA200-53.57% Volume41,004 Change-2.05%
Apr-26-21Resumed Credit Suisse Outperform $12
Nov-23-20Initiated SVB Leerink Outperform $27
Nov-23-20Initiated Credit Suisse Outperform $29
Nov-23-20Initiated BofA Securities Buy $21
Jul-28-21 04:31AM  
Jul-13-21 08:00AM  
Jun-22-21 12:40PM  
Jun-10-21 03:31PM  
Jun-02-21 08:00AM  
May-11-21 08:00AM  
May-06-21 08:00AM  
May-04-21 08:30AM  
Apr-29-21 05:49AM  
Apr-19-21 06:38AM  
Apr-15-21 08:00AM  
Mar-29-21 08:30AM  
Mar-23-21 10:26AM  
Mar-15-21 07:30AM  
Feb-09-21 08:00AM  
Jan-29-21 01:33AM  
Jan-08-21 08:00AM  
Jan-04-21 04:01PM  
Dec-11-20 08:06AM  
Nov-30-20 08:00AM  
Nov-23-20 04:01PM  
Oct-29-20 01:28PM  
Oct-28-20 09:10PM  
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lindmark BertilChief Medical OfficerJun 28Buy5.262,00010,5202,000Jun 28 04:00 PM
Schambye Hans T.Chief Executive OfficerJun 24Buy5.113,00015,33042,928Jun 24 04:00 PM
Winslow GarrettGeneral CounselJun 23Buy4.802,0009,6002,000Jun 23 04:00 PM
Freve JonathanChief Financial OfficerJun 23Buy4.742,0009,4802,000Jun 23 04:00 PM